Residual risk in statin-treated patients: Future therapeutic options-Reference-Cited by-同舟云学术

Residual risk in statin-treated patients: Future therapeutic options

Published:2007-11 Issue:6 Volume:9 Page:499-505
ISSN:1523-3782
Container-title:Current Cardiology Reports
language:en
Short-container-title:Curr Cardiol Rep

Author:

Campbell Catherine Y.,Rivera Juan J.,Blumenthal Roger S.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF02938395.pdf

Reference38 articles.

1. Shepherd J, Cobbe SM, Ford I, et al.:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group.N Engl J Med 1995,333:1301–1307.

2. Downs JR, Clearfield M, Weis S, et al.:Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA 1998,279:1615–1622.

3. Sever PS, Dahlof B, Poulter NR, et al.:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet 2003,371:1149–1158.

4. Scandinavian Simvastatin Survival Study Group:Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet 1994,344:1383–1389.

5. Sacks FM, Pfeffer MA, Moye LA, et al.:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators.N Engl J Med 1996,335:1001–1009.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between triglyceride glucose index and adverse clinical outcomes in patients with acute myocardial infarction and LDL-C≤1.8 mmol/L who underwent percutaneous coronary intervention: a prospective cohort study;Frontiers in Endocrinology;2024-01-18

2. Thymoquinone (TQ) Inhibits Inflammation and Migration of THP-1 Macrophages: Mechanistic Insights into the Prevention of Atherosclerosis Using In-Vitro and In-Silico Analysis;Current Issues in Molecular Biology;2022-04-15

3. Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation;Methods in Molecular Biology;2022

4. Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions;Methods in Molecular Biology;2022

5. The Predictive Value of Lp(a) for Adverse Cardiovascular Event in ACS Patients With an Achieved LDL-C Target at Follow Up After PCI;Journal of Cardiovascular Translational Research;2021-06-21